Ebastine

DB11742ApprovedInvestigationalWithdrawnSmall molecule

Ebastine is a second generation H1-receptor antagonist useful in the treatment of allergic rhinitis and urticaria. Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS).

Chemical structure of Ebastine
Mechanism
Curator reviewed · 1 reference
Formula / weight
C32H39NO2 · 469.6576 g/mol (avg)

Resolves to

Compound
UNIITQD7Q784P1CAS90729-43-4ChEMBLCHEMBL305660ChEBI31528PubChem3191
Clinical / RWD
RxNorm23796ATCR06AX22PharmGKBPA166304861
Structure
InChIKeyMJJALKDDGIKVBE-UHFFFAOYSA-NSMILESCC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
Targets
P35367HRH1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
817Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
270Marketed productsAcross 6 countries and 19 labellers
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
10+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ebastine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In